Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GD2/PSMA/CD276 4SCAR-expressing T cells

A preparation of T cells that are genetically engineered to express fourth generation chimeric antigen receptors (4SCARs) targeting the three tumor-associated antigens (TAAs) prostate-specific membrane antigen (PSMA), disialoganglioside (GD2), and the immune checkpoint molecule protein B7-homologue 3 (B7-H3, CD276), coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-GD2/PSMA/CD276-4SCAR-expressing T cells are directed to and induce selective toxicity in GD2-, PSMA- and CD276-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T cells and enhances safety of this agent. PSMA, a type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors, including brain tumor, neuroblastoma (NB) and some lymphoma tumor tissues. CD276, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is highly expressed on many solid tumors including NB. It is a negative regulator of the T-cell activation and plays a key role in tumor evasion. GD2 is overexpressed on the surface of NB cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T cells and antitumor activity.
Synonym:anti-GD2/anti-PSMA/anti-CD276 4SCAR T cells
GD2/PSMA/CD276 4SCAR T cells
multi-4SCAR-T cells
Search NCI's Drug Dictionary